News Release

HIV elimination in South Africa could be achieved by current treatment policy

Peer-Reviewed Publication

PLOS

The current antiretroviral treatment policy in South Africa could lead to elimination of HIV within the country over the next 24 to 34 years, but a universal test and treat (UTT) approach could achieve elimination 10 years earlier according to new research published this week in PLOS Medicine.

The research, which is an international collaboration led by Jan Hontelez from Erasmus MC, University Medical Center Rotterdam, Netherlands, used nine increasingly sophisticated mathematical models aimed to test the time frames in which expanded access to antiretroviral viral therapy could lead to HIV elimination in South Africa..

Antiretroviral therapy is usually started when a person's CD4 count (a type of white blood cell) falls below 350 cells/μl blood, but evidence exists that treatment of all HIV-positive individuals, regardless of their CD4 count, could reduce HIV transmission by reducing the infectiousness of HIV-positive individuals ("treatment as prevention"). Previous studies have suggested that scale up of HIV treatment could lead to elimination of HIV although within differing time scales.

In their study Hontelez and colleagues systematically assessed a UTT intervention (defined as annual screening of individuals age 15+ years and immediate initiation of antiretroviral therapy (ART) for all HIV-infected adults starting in 2012 and scaled up to 90% coverage by 2019) by simulating the HIV epidemic in South Africa with increasing degrees of complexity and realism—including sexual networks, HIV stages with different degrees of infectiousness, and updated treatment effectiveness assumptions to explore the timeframes to elimination.

All the models replicated the prevalence of HIV in South Africa (the proportion of the population that was HIV-positive) between 1990 and 2010, and all predicted that UTT would result in HIV elimination (less than one new infection per 1,000 person-years). However, whereas the simplest model predicted that UTT would eliminate HIV after seven years, the more complex, realistic models predicted elimination at much later time points. Importantly, the most comprehensive model predicted that, although elimination would be reached after about 17 years of UTT, the current strategy of ART initiation for HIV-positive individuals at a CD4 cell count at or below 350 cells/μl would also lead to HIV elimination, albeit ten years later than UTT.

In a related Perspective article Nathan Ford and Gottfried Hirnschall (uninvolved in the study) from the World Health Organization reflect on the research noting, "[t]he case for ART impact on HIV transmission is proven. The priority now is to help translate this concept into benefits for patients and communities by identifying and implementing approaches that work to maximize early HIV testing and ART uptake and long-term retention in care."

###

Research Article

Funding: This work is supported by the HIV Modelling Consortium. The HIV Modelling Consortium is supported by a grant from the Bill & Melinda Gates Foundation to Imperial College London. This work is also supported by the US National Institutes of Health (1R01MH083539) and (1R01-HD058482). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: TBH and MLN are members of the PLOS Medicine Editorial Board. TBH is the director of the HIV Modelling Consortium, a project funded by the Bill & Melinda Gates Foundation, which contributed funding toward this study. TBH did not have a role in deciding that funding should be awarded to this team. All other authors have declared that no competing interests exist.

Citation: Hontelez JAC, Lurie MN, Bärnighausen T, Bakker R, Baltussen R, et al. (2013) Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. PLoS Med 10(10): e1001534. doi:10.1371/journal.pmed.1001534

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001534

Contact:

Jan Hontelez
Department of Public Health, Erasmus MC
University Medical Center Rotterdam
PO Box 2040
+31 6 44730408
+27 79 5980219
j.hontelez@erasmusmc.nl

Perspective Article

Funding: No specific funding was received to write this article.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Ford N, Hirnschall G (2013) Modelling the Strategic Use of Antiretroviral Therapy for the Treatment and Prevention of HIV. PLoS Med 10(10): e1001535. doi:10.1371/journal.pmed.1001535

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001535

Contact:

Nathan Ford
World Health Organization
SWITZERLAND
+27 82 852 1886
nathan.ford@joburg.msf.org; fordn@who.int


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.